Evidence map›Paper›PMID 31299106›Full record

ArticleCancer2019

Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission.

Samuel D Slavin, Alyssa Fenech, Amanda L Jankowski, Gregory A Abel, Andrew M Brunner, David P Steensma, Amir T Fathi, Daniel J DeAngelo, Martha Wadleigh, Gabriela S Hobbs and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Research priorities to address supportive care needs in acute myeloid leukaemia (AML)-results from a Delphi survey.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Samuel D SlavinDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-7208-1351
Alyssa FenechCancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Amanda L JankowskiCancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Gregory A AbelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Andrew M BrunnerCancer Center, Massachusetts General Hospital, Boston, Massachusetts.
David P SteensmaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-5130-9284
Amir T FathiCancer Center, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-4907-6447
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Martha WadleighDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Gabriela S HobbsCancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Philip C AmreinCancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jennifer S TemelCancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Areej El-JawahriCancer Center, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-3556-1495
Harvard University · USMassachusetts General Hospital · US

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9M
Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2017 to 2021
$10.6M
Optimizing Palliative and End of Life Care for Patients with CancerK24CA181253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TEMEL, JENNIFER SUE · 2014 to 2018
$737k
National Cancer Institute's Federal Share Program K24 CA 181253NCI NIH HHS K12 CA087723NCI NIH HHS K24 CA181253NCI NIH HHS P01 CA066996NCI NIH HHS P50 CA206963NIH HHS
6 · The paper itself

Abstract

backgroundOlder adults with acute myeloid leukemia (AML) are often assumed to have poor outcomes after admission to the intensive care unit (ICU). However, little is known about ICU utilization and post-ICU outcomes in this population.

methodsThe authors conducted a retrospective analysis for 330 patients who were 60 years old or older and were diagnosed with AML between 2005 and 2013 at 2 hospitals in Boston.They used descriptive statistics to examine the proportion of patients admitted to the ICU as well as their mortality and functional recovery. They used logistic regression to identify risk factors for in-hospital mortality.

resultsNinety-six patients (29%) were admitted to the ICU, primarily because of respiratory failure (39%), septic shock (28%), and neurological compromise (9%). The proportions of patients who survived to hospital discharge, 90 days, and 1 year were 47% (45 of 96), 35% (34 of 96), and 30% (29 of 96), respectively. At 90 days, 76% of the patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and 86% were in complete remission (CR) and/or continued to receive AML-directed therapy. In a multivariate analysis, a poorer baseline ECOG PS score (odds ratio, 2.76; P = .013) and the need for 2 or more life-sustaining therapies (ie, vasopressors, invasive ventilation, and/or renal replacement therapy; odds ratio, 12.4; P < .001) were associated with increased odds of in-hospital mortality.

conclusionsAlthough almost one-third of older patients with AML are admitted to an ICU, nearly half survive to hospital discharge with good functional outcomes. The baseline performance status and the need for 2 or more life-sustaining therapies predict hospital mortality. These data support the judicious use of ICU resources for older patients with AML.

Indexed as

Acute DiseaseAgedBostonFemaleHospitalizationHospital MortalityHumansIntensive Care UnitsLeukemia, MyeloidLogistic ModelsMaleMiddle AgedOutcome Assessment, Health CarePrognosisRetrospective Studiesactivities of daily livingacute myeloid leukemiacritical carein-hospital mortality

Identifiers

PMID31299106
PMCPMC6788935
OpenAlexW2960420612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.